Search clinical trials for: Bromefenac

Total 56 results

Bp Consulting, Inc

Completed

Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

Diabetic Macular Edema

United States
Bausch & Lomb Incorporated

Completed

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Dry Eye Syndrome

United States
Melissa Toyos
Bausch & Lomb Incorporated

Completed

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery (QD)

Inflammation | Cataract | Retinal Edema

United States
Seoul National University Hospital

Recruiting

Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy

Familial Exudative Vitreoretinopathies

Korea, Republic of
Johns Hopkins University

Withdrawn

Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.

Cystoid Macular Edema

United States
Kyungpook National University Hospital

Completed

Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification

Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. (PRO-155/IV)

Ocular Inflammation | Ocular Pain | Pterygium | Post-surgical Inflammation

Mexico
Bp Consulting, Inc

Completed

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

Intraocular Pressure

United States
Ophthalmic Consultants of Boston
Bausch & Lomb Incorporated

Unknown

Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser

Diabetic Macular Edema

United States
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

Dry Eye Disease

United States
Bausch & Lomb Incorporated

Completed

Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Pain | Inflammation

United States
Bausch & Lomb Incorporated

Completed

Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Pain | Inflammation | Cataract

United States
Bausch & Lomb Incorporated

Completed

Efficacy and Safety of Bromfenac Ophthalmic Solution

Cataract Surgery

United States
Bausch & Lomb Incorporated

Completed

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Cataract

United States
Bausch & Lomb Incorporated

Completed

Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery

Pain | Inflammation

United States
Sun Yat-sen University
Ministry of Health, China

Completed

Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery

Cataract

China
Babasaheb Ambedkar Memorial Hospital

Completed

Comparison of Treatments in Diabetic Macular Edema

Diabetic Macular Edema
Florida Eye Microsurgical Institute
Bausch & Lomb Incorporated

Completed

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

Dry Eye Disease | Ocular Comfort

United States
Toyos Clinic
Bausch & Lomb Incorporated

Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Inflammation | Pseudophakia
Innovative Medical

Completed

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

Cataract

United States
Innovative Medical

Completed

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Vitrectomy

United States
Hospital de La Luz

Unknown

Topical Bromfenac for Intraoperative Miosis and Pain Reduction

Cataract

Mexico
Oregon Health and Science University
Genentech, Inc.

Completed

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Bucci Laser Vision Institute
Allergan

Completed

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

Post Operative Anterior Chamber Inflammation (Flare)

United States
Wills Eye

Completed

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

Pain | Pain, Acute | Intravitreal Injection

United States, Canada
Cindy Hutnik
Glaucoma Research Society of Canada

Unknown

NSAID vs Steroid in Trabeculectomy Wound Management

Glaucoma
Frank A. Bucci, Jr., M.D.
Allergan

Completed

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification

Cataracts

United States
Arcispedale Santa Maria Nuova-IRCCS

Completed

Bromfenac Versus Dexamethasone After Cataract Surgery (BVD)

Inflammation Eye

Italy
Università degli Studi di Brescia

Completed

NSAIDs and PGE2 Levels in Vitrectomy Patients

Vitreous Inflammation
Center For Excellence In Eye Care

Completed

Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening

Cystoid Macular Edema, | Retinal Thickening

United States
Bausch & Lomb Incorporated

Completed

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Bausch & Lomb Incorporated

Completed

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

Postoperative Complications | Cataract

United States
Bausch & Lomb Incorporated

Completed

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Cataract

United States
Arcispedale Santa Maria Nuova-IRCCS

Completed

Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (REPEX)

Cataract | Pseudoexfoliation Syndrome

Italy
Virdi Eye Clinic

Completed

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

Myopia

United States
Zhongshan Ophthalmic Center, Sun Yat-sen University

Completed

Effect of Bromfenac on Pain Related to Pterygium Surgery

Pain | Pterygium

China
Sun Pharmaceutical Industries Limited

Completed

Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects (ISV-303)

Ocular Inflammation
Sun Pharmaceutical Industries Limited

Completed

Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

Cataract
Sun Pharmaceutical Industries Limited

Completed

Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

Ocular Inflammation
Klinički Bolnički Centar Zagreb
University of Zagreb

Completed

PCME Prevention in Patients With NPDR

Cystoid Macular Edema Following Cataract Surgery

Croatia
Silverstein Eye Centers
Bausch & Lomb Incorporated; Churchhill Communications; Statistics & Data Corporation

Completed

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

Treatment of Ocular Inflammation Associated With Cataract Surgery
Sun Pharmaceutical Industries Limited

Completed

Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

Ocular Inflammation
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers. (PRO-155)

Inflammation | Cataract

Mexico
University of Trieste

Completed

PGE2 Levels in Patient Treated With NSAIDs

Ocular Inflammation

Italy
Bp Consulting, Inc

Completed

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Acute Pseudophakic Cystoid Macular Edema

United States
University of Wisconsin, Madison

Completed

Control of Pain in Intravitreal Injections Using Topical NSAIDs (COPIVIN)

Intravitreal Injections | IVI

United States
Innovative Medical

Completed

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects

Cataract

United States
Optall Vision

Recruiting

Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms (PBO)

Presbyopia

Mexico
Carolina Eyecare Physicians, LLC
Science in Vision; Imprimis Pharmaceuticals, Inc.

Completed

Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen

Cataract

United States
University of Aarhus
The Ministry of Science, Technology and Innovation, Denmark

Completed

Glucocorticoid Induced Whole Body Catabolisme

Whole Body Catabolisme Induced by Glucocorticoids

Denmark

3

Subscribe